Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.

David M. O'Malley,Lainie P. Martin,Lucy Gilbert,Ignace Vergote,Ursula A. Matulonis,Michael J. Birrer,Cesar M. Castro,Karim Malek,Antonio González-Martín,Kathleen N. Moore

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.

2018

David M. O'Malley
Lainie P. Martin
Lucy Gilbert
Ignace Vergote
Ursula A. Matulonis
Michael J. Birrer
Cesar M. Castro
Karim Malek
Antonio González-Martín
Kathleen N. Moore

5549Background: Mirvetuximab soravtansine is an ADC, comprising a FRα-binding antibody linked to the tubulin-disrupting maytansinoid DM4, currently being evaluated in combination with bevacizumab a...

Keywords:

Folate Receptor Alpha
Ovarian cancer
Bevacizumab
Pathology
MIRVETUXIMAB SORAVTANSINE
Cancer research
Antibody-drug conjugate
Medicine
Antibody
in patient
activity profile

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations